Geode Capital Management
CYT

Geode Capital Management’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

Geode Capital Management’s Portfolio CYT Stock Details CYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-177,930
Closed -$541K – 4665
2023
Q4 		$541K Buy
177,930
+14,393
+9% +$43.7K ﹤0.01% 3584
2023
Q3 		$465K Buy
163,537
+44,505
+37% +$123K ﹤0.01% 3627
2023
Q2 		$309K Hold
119,032
– – ﹤0.01% 3841
2023
Q1 		$217K Buy
119,032
+1,900
+2% +$3.09K ﹤0.01% 4008
2022
Q4 		$193K Buy
117,132
+3,504
+3% +$5.62K ﹤0.01% 4124
2022
Q3 		$218K Buy
113,628
+36,041
+46% +$94K ﹤0.01% 4164
2022
Q2 		$231K Sell
77,587
-148,662
-66% -$380K ﹤0.01% 4174
2022
Q1 		$852K Buy
226,249
+88,089
+64% +$501K ﹤0.01% 3688
2021
Q4 		$1.57M Buy
138,160
+43,281
+46% +$660K ﹤0.01% 3494
2021
Q3 		$1.67M Buy
94,879
+78,599
+483% +$1.47M ﹤0.01% 3438
2021
Q2 		$348K Buy
+16,280
New +$305K ﹤0.01% 4098

Other funds holding CYT

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return
LC
Lindbrook Capital Calabasas, California $1.08B AUM 10.14% 1-Year Est. Return

Geode Capital Management's CYT Position: Q1 2024 in Review

Geode Capital Management sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q1 2024, closing a stake of 177,930 shares — an estimated $541K sold.

Geode Capital Management first reported a position in CYT in Q2 2021 and held it in 11 quarters. The position peaked at $1.67M in Q3 2021. 4 funds tracked by Wall St. Rank hold CYT as of Q1 2024.

  • Geode Capital Management reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Geode Capital Management sold 177,930 Cyteir Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $541K.
  • Geode Capital Management first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q2 2021 and held it in 11 quarters.
  • Geode Capital Management's Cyteir Therapeutics, Inc. Common Stock position peaked at $1.67M in Q3 2021.
  • 4 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Geode Capital Management's 13F filing for Q1 2024, filed 13 May 2024.